- 全部删除
您的购物车当前为空
Botensilimab (AGEN 1181),一种针对细胞毒性T淋巴细胞抗原4 (CTLA-4) 的人源化单克隆抗体,既能激活先天性免疫也能激活适应性免疫,主要应用于癌症研究领域。

为众多的药物研发团队赋能,
让新药发现更简单!
Botensilimab (AGEN 1181),一种针对细胞毒性T淋巴细胞抗原4 (CTLA-4) 的人源化单克隆抗体,既能激活先天性免疫也能激活适应性免疫,主要应用于癌症研究领域。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 2,150 | In stock | |
| 5 mg | ¥ 5,160 | In stock | |
| 10 mg | ¥ 6,950 | In stock | |
| 25 mg | ¥ 10,500 | In stock | |
| 50 mg | ¥ 14,200 | In stock |
Botensilimab 相关产品
| 产品描述 | Botensilimab (AGEN 1181), a humanized monoclonal antibody targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4), functions as an activator of both innate and adaptive immunity. It is currently being researched for its potential application in cancer treatment [1]. |
| CAS No. | 2408310-37-0 |
| 颜色 | Transparent |
| 物理性状 | Liquid |
| 存储 | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
评论内容